Societe Generale Initiates Coverage on GlaxoSmithKline (GSK)

By admin | 6 years ago

Research analysts at Societe Generale began coverage on shares of GlaxoSmithKline (NYSE: GSK) in a report released on Thursday. The firm set a “buy” rating on the stock.

Shares of GlaxoSmithKline traded up 0.70% during mid-day trading on Thursday, hitting $45.82. GlaxoSmithKline has a 52 week low of $38.76 and a 52 week high of $47.48. The company has a market cap of $113.7 billion and a P/E ratio of 14.12.

GlaxoSmithKline last announced its earnings results on Wednesday, April 25th. The company reported $0.27 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.29 by $0.02. The company’s quarterly revenue was up .8% on a year-over-year basis. On average, analysts predict that GlaxoSmithKline will post $0.93 earnings per share next quarter.

Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note to investors on Monday, April 30th. They now have a $49.00 price target on the stock.

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

About the author